We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sinotherapeutics

News List

Vitruvias, Sinotherapeutics launch approved version of Propafenone ER in the U.S. biospectrumasia
March 12, 2019
Rythmol SR, known generically as propafenone hydrochloride, is an antiarrhythmic drug supplied in extended-release capsules of 225, 325 and 425 mg for oral administration
Vitruvias Therapeutics Inc. Launches Shanghai-Based Sinotherapeutics’s Approved Version of Propafenone ER in the U.S. pharmafocusasia
March 12, 2019
Vitruvias Therapeutics Inc., an Auburn, Alabama-based finished-dose generic drug company, and Sinotherapeutics Inc., a Shanghai-based generic drug company, announced they have launched a bioequivalent FDA-approved version of Rythmol SR.